港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

海西新药

134.800

+2.8002.12%

成交量：3.33万

成交额：442.37万

市值：106.10亿

市盈率：- -

高：135.500

开：132.200

低：130.000

收：132.000

52周最高：147.000

52周最低：97.500

股本：7,870.73万

香港流通股本：7,870.73万

量比：0.33

换手率：0.04%

股息：- -

股息率：- -

净资产收益率：28.75%

总资产收益率：12.62%

市净率：17.93

市盈率(LYR):- -

市销率: 20.79

数据加载中...

总览公司新闻资讯公告

到手的“肉签”飞了？海西新药是延迟上市还是被迫中止？

手握口服眼药“王炸”，这家公司今日港股IPO

海西新药(02637)将延迟上市

海西新药将延迟上市，需额外时间完成公告及获取监管批准

老虎暗盘 | 海西新药涨超100%，中签一手赚超4300港元

老虎资讯综合

海西新药IPO：仿创结合，点亮内地制药创新之路

春雷資本 HK

港股IPO动态：今日聚水潭、海西新药申购

智通港股投资日志|10月14日

东鹏饮料、坦博尔递表港交所；海西新药10月9日开启招股丨港交所早参

每日经济新闻

新股招股 | 海西新药招股，一手入场费4363.57港元

老虎资讯综合

海西新药(02637.HK)预计10月17日上市引入Harvest Oriental作为基石

海西新药(02637)拟全球发售1150万股预计10月17日上市

一图解码：海西新药过港交所聆讯仿创双轨驱动业绩稳增

海西新药通过上市聆讯：5个月营收2.5亿期内利润9021万

海西新药通过港交所聆讯华泰国际和招银国际为联席保荐人

证券时报网

新股消息 | 海西新药通过港交所聆讯，四款仿制药入选国家带量采购计划

毛利率逼近恒瑞，仿制药年赚1.4亿，海西新药为何二次递表港股？

海西新药递表港股：36名销售撑起4.66亿营收，毛利率超80%逼近恒瑞，靠仿制药年赚1.4亿，关联资金交易引关注

创业最前线

海西新药冲击IPO，用仿制药养创新药，销售费用率较高

二次递表，海西新药国有股权被稀释之迷

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02637/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新药","latestPrice":134.8,"timestamp":1763366893757,"preClose":132,"halted":0,"volume":33300,"delay":0,"floatShares":78707270,"shares":78707270,"eps":0,"marketStatus":"已收盘","change":2.8,"latestTime":"11-17 16:08:13","open":132.2,"high":135.5,"low":130,"amount":4423690,"amplitude":0.041667,"askPrice":135.4,"askSize":50,"bidPrice":134.8,"bidSize":100,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":5,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":132,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":0.328564,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02637\",,,,,undefined,":{"symbol":"02637","floatShares":78707270,"roa":"12.62%","roe":"28.75%","lyrEps":0,"volumeRatio":0.328564,"shares":78707270,"dividePrice":0,"high":135.5,"amplitude":0.041667,"preClose":132,"low":130,"week52Low":97.5,"pbRate":"17.93","psRate":"20.79","week52High":147,"institutionHeld":0,"latestPrice":134.8,"committee":0.333333,"eps":0,"divideRate":0,"volume":33300,"delay":0,"ttmEps":0,"open":132.2,"prevYearClose":86.4,"prevWeekClose":132,"prevMonthClose":119.8,"prevQuarterClose":86.4,"fiveDayClose":129.4,"twentyDayClose":86.4,"sixtyDayClose":86.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02637\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02637\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02637","date":"2025-11-14","current":69.713569,"percent":0.842105,"low":41.43616,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"high":76.371175,"avg":61.983096,"sd":7.689241,"marketCap":10389359640},"quantilePoints":[{"date":"2025-10-16","current":41.43616,"twenty":41.43616,"median":41.43616,"eighty":41.43616,"marketCap":6150186077},{"date":"2025-10-24","current":58.044665,"twenty":53.788314,"median":54.742854,"eighty":58.044665,"marketCap":8618446065},{"date":"2025-10-31","current":63.409996,"twenty":54.11413,"median":58.177187,"eighty":60.582738,"marketCap":9429130946},{"date":"2025-11-07","current":65.038519,"twenty":55.071217,"median":59.875924,"eighty":63.533346,"marketCap":9665252756},{"date":"2025-11-14","current":69.713569,"twenty":57.493757,"median":61.562796,"eighty":68.778725,"marketCap":10389359640}],"updateTime":1763367875852},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02637\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576097082","title":"到手的“肉签”飞了？海西新药是延迟上市还是被迫中止？","url":"https://stock-news.laohu8.com/highlight/detail?id=2576097082","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576097082?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 17:23","pubTimestamp":1760693006,"startTime":"0","endTime":"0","summary":"海西新药本预期H股于10月17日上午九时正在联交所开始买卖，所以公司上述公告一出立马引发市场热议。因为与此前首钢朗泽IPO紧急叫停的原因不同，海西新药是在开启暗盘交易后宣布暂缓挂牌。而海西新药也成为自2023年港交所FINI系统落地后，首只在暗盘交易后因未能刊发配发结果而延迟上市的新股公司。据悉，海西新药的创新药管线包括1个2期临床项目、3个临床前项目，覆盖了肿瘤、眼科及呼吸系统疾病领域需求。","market":"fut","thumbnail":"https://static.tigerbbs.com/266ab84342c6ca65b538d0b42bc1dc4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/266ab84342c6ca65b538d0b42bc1dc4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"66a4019331b03d4321cdeb149dbc6c5b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356368.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"到手的“肉签”飞了？海西新药是延迟上市还是被迫中止？","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637"],"gpt_icon":1},{"id":"2576377742","title":"手握口服眼药“王炸”，这家公司今日港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2576377742","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576377742?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 08:09","pubTimestamp":1760659773,"startTime":"0","endTime":"0","summary":"安必力的成功得益于其低不良药物反应、无心脏毒性及增强胃肠蠕动的特性，这使其成为多潘立酮的有效替代品。该产品于2024年为公司带来1.87亿元收入，市场份额高达59.3%，在中国市场中排名第一。这意味着海西新药在为其创新药“烧钱”时，拥有比纯粹的Biotech公司更强的抗风险能力和更从容的研发节奏。罗氏的法瑞西单抗是全球首个眼底双抗药物，上市后法瑞西单抗迅速放量，目前该产品已被纳入医保目录，预计将会对现有市场格局造成巨大冲击。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101708121594cdeb73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101708121594cdeb73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02637","06978","BK1161"],"gpt_icon":1},{"id":"2575744597","title":"海西新药(02637)将延迟上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2575744597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575744597?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 21:26","pubTimestamp":1760621195,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药(02637)公布，因需要额外时间完成配发结果公告的定稿及获取监管机构批准，公司的上市时间表将会顺延。董事会将在切实可行情况下尽快向市场提供最新资料。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"66a4019331b03d4321cdeb149dbc6c5b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637"],"gpt_icon":0},{"id":"2575744592","title":"海西新药将延迟上市，需额外时间完成公告及获取监管批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2575744592","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575744592?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 21:26","pubTimestamp":1760621195,"startTime":"0","endTime":"0","summary":"将尽快向市场提供最新资料。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"66a4019331b03d4321cdeb149dbc6c5b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"海西新药将延迟上市，需额外时间完成公告及获取监管批准","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02637"],"gpt_icon":0},{"id":"1147940289","title":"老虎暗盘 | 海西新药涨超100%，中签一手赚超4300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1147940289","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147940289?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 16:15","pubTimestamp":1760602538,"startTime":"0","endTime":"0","summary":"10月16日，$海西新药$暗盘涨超100%，总市值突破136亿港元！公司每股定价86.4港元，每手50股，将于10月17日正式挂牌交易。海西新药是一家处于商业化阶段的制药公司，集研发、生产及销售能力于一体，具备在研创新药的管线，已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药，并建立拥有4款在研创新药的管线。其中进度最快的是针对骨肉瘤的C019199，今年下半年开展III期试验。","market":"us","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"de34d0a9c732ef230ac1598ddf0f7133","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"gpt_icon":1},{"id":"2575789900","title":"海西新药IPO：仿创结合，点亮内地制药创新之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2575789900","media":"春雷資本 HK","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575789900?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 18:26","pubTimestamp":1760524015,"startTime":"0","endTime":"0","summary":"在公司于截至最后实际可行日期已获国家药监局批准的15款仿制药当中，有四款入选国家带量采购计划，并继续为公司带来庞大的收益贡献。我们亦有四款药物入选省级VBP计划。入选国家VBP计划的四款药物包括安必力、海慧通、瑞安妥、赛西福。募资热度全览内地制药公司海西新药 10月9日起至14日招股。海西新药预期将于10月17日挂牌买卖，华泰国际、招银国际为联席保荐人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015193008a6bab4b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015193008a6bab4b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","01477","02637"],"gpt_icon":1},{"id":"2575235065","title":"港股IPO动态：今日聚水潭、海西新药申购","url":"https://stock-news.laohu8.com/highlight/detail?id=2575235065","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575235065?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 06:13","pubTimestamp":1760393595,"startTime":"0","endTime":"0","summary":"格隆汇10月14日｜今日聚水潭(6687.HK)、海西新药(2637.HK)申购，无新股上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014061409972bfda1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014061409972bfda1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02637"],"gpt_icon":0},{"id":"2575528303","title":"智通港股投资日志|10月14日","url":"https://stock-news.laohu8.com/highlight/detail?id=2575528303","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575528303?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 00:00","pubTimestamp":1760371203,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年10月14日，港股上市公司投资日志如下：    类别 公司  新股活动聚水潭(招股中)海西新药(招股中) 股东大会召开日多想云新火科技控股HTSC富一国际控股中国银行赣锋锂业兆邦基生活 分红派息爪哇控股（派息日）亚太卫星（派息日）吉宏股份（除净日）美丽华酒店（派息日）中国光大绿色环保（派息日）HERALD HOLD（派息日）弥明生活百货（除净日）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06687","06696","BK1137","02637"],"gpt_icon":0},{"id":"2574916759","title":"东鹏饮料、坦博尔递表港交所；海西新药10月9日开启招股丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2574916759","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574916759?lang=zh_cn&edition=fundamental","pubTime":"2025-10-10 00:40","pubTimestamp":1760028033,"startTime":"0","endTime":"0","summary":"｜2025年10月10日星期五｜NO.1东鹏饮料再度递表港交所据港交所10月9日披露，功能饮料品牌“东鹏特饮”的母公司东鹏饮料（605499.SH，股价301.51元）向港交所主板提交上市申请书，华泰国际、摩根士丹利、瑞银集团为联席保荐人。这是继其于2025年4月3日首次递表失效后的再次递表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510103529805527.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510103529805527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02637"],"gpt_icon":0},{"id":"1196812747","title":"新股招股 | 海西新药招股，一手入场费4363.57港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196812747","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196812747?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 07:54","pubTimestamp":1759967683,"startTime":"0","endTime":"0","summary":"$海西新药$ 于2025年10月9日-10月14日招股，拟全球发售1150万股，香港公开发售占约10%，国际发售占约90%。申购阶梯：每手50股，入场费4363.57港元。基石投资者海西新药引入Harvest Oriental为基石投资者，投资金额2200万美元。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549f9380bf037a1302d7021f68ae91fd","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549f9380bf037a1302d7021f68ae91fd"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股 | 海西新药招股，一手入场费4363.57港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"gpt_icon":1},{"id":"2574909129","title":"海西新药(02637.HK)预计10月17日上市 引入Harvest Oriental作为基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2574909129","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574909129?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 07:37","pubTimestamp":1759966621,"startTime":"0","endTime":"0","summary":"　　截至最后实际可行日期，集团已就15款仿制药获得国家药监局批准，并建立拥有四款在研创新药的管线，使集团成为中国制药行业的主要市场参与者。　　集团已与基石投资者订立基石投资协议，据此，基石投资者已同意在若干条件规限下，按发售价认购或购买总金额约2200万美元可购买数目的发售股份。　　假设发售价为每股股份78.14港元，集团估计将从全球发售收取所得款项净额约8.48亿港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251009/31690886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02637"],"gpt_icon":0},{"id":"2574906978","title":"海西新药(02637)拟全球发售1150万股 预计10月17日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2574906978","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574906978?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 07:09","pubTimestamp":1759964964,"startTime":"0","endTime":"0","summary":"发售价为每股发售股份69.88-86.40港元，每手50股，预期H股将于2025年10月17日上午九时正在联交所开始买卖。该公司在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。截至最后实际可行日期，该公司已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药;根据灼识咨询的资料，该等治疗领域占2023年中国医药销售总额的25%以上。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637"],"gpt_icon":0},{"id":"2572597714","title":"一图解码：海西新药过港交所聆讯 仿创双轨驱动 业绩稳增","url":"https://stock-news.laohu8.com/highlight/detail?id=2572597714","media":"IPO解码","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572597714?lang=zh_cn&edition=fundamental","pubTime":"2025-10-02 16:11","pubTimestamp":1759392676,"startTime":"0","endTime":"0","summary":"历经两次递表后，海西新药通过了港交所聆讯，并于9月29日更新了聆讯后招股书；由华泰国际和招银国际担任联席保荐人。海西新药在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。据披露，海西新药的业务采用了新颖的双轨模式，包括仿制药及在研创新药。于往绩记录期间，海西新药的收益来自13种获批准产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251002161231a4511084&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251002161231a4511084&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0918141887.USD","LU0348814723.USD","LU1105468828.SGD","LU0348825331.USD","LU0106959298.USD","LU0084288322.USD","LU0251144936.SGD","LU0516422440.USD","LU0149534421.HKD","LU0577902371.SGD","SG9999001051.SGD","LU0516423174.USD","BK1610","LU0762540952.USD","LU0607220059.USD","HEXmain","LU0821914370.USD","LU1044875133.USD","LU0359202008.SGD","LU0577902298.EUR","LU0791591158.USD","LU0831103253.SGD","HKXCY","LU0630378429.USD","LU0762542818.HKD","IE00B3T34201.USD","LU0197773673.USD","LU0979878070.USD","SG9999001846.SGD","LU0197773160.USD","LU0650527681.SGD","LU0061477393.USD","LU0791590937.USD","LU0048597586.USD","LU2226246903.HKD","LU0577902538.SGD","LU1242518931.SGD","LU0169518387.USD","LU2039709279.SGD","BK1131","LU0648948544.HKD","LU1051768304.USD","LU0886674414.USD","00388","80388","LU1048588211.SGD","LU1282649067.USD","LU0634319403.HKD","LU0417516902.SGD","02637"],"gpt_icon":0},{"id":"2571398476","title":"海西新药通过上市聆讯：5个月营收2.5亿 期内利润9021万","url":"https://stock-news.laohu8.com/highlight/detail?id=2571398476","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571398476?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 09:21","pubTimestamp":1759195303,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司（简称：“海西新药”）日前通过上市聆讯，准备在港交所上市。招股书显示，海西新药2022年、2023年、2024年营收分别为2.12亿、3.16亿元、4.67亿元；","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250930/6389482089873612353697863.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250930/6389482089873612353697863.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n31340/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["02637"],"gpt_icon":0},{"id":"2571621903","title":"海西新药通过港交所聆讯 华泰国际和招银国际为联席保荐人","url":"https://stock-news.laohu8.com/highlight/detail?id=2571621903","media":"证券时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571621903?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 08:15","pubTimestamp":1759191300,"startTime":"0","endTime":"0","summary":"海西新药已通过港交所上市聆讯，华泰国际和招银国际为其联席保荐人。公司是一家商业化阶段的制药企业，拥有研发、生产和销售能力，并有在研创新药管线。公司已获批14款仿制药，并拥有四款在 ...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20250930/c671528081.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250930/c671528081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02637"],"gpt_icon":0},{"id":"2571369634","title":"新股消息 | 海西新药通过港交所聆讯，四款仿制药入选国家带量采购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2571369634","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571369634?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 06:29","pubTimestamp":1759184946,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所9月29日披露，福建海西新药创制股份有限公司通过港交所主板上市聆讯，华泰国际和招银国际为其联席保荐人。公司目前已就14款仿制药获得国家药监局批准，并建立拥有四款在研创新药的管线。仿制药上，在已获国家药监局批准的15款仿制药当中，有四款入选国家带量采购计划，并继续带来庞大的收益贡献。赛西福于2024年及截至2025 年5月31日止五个月分别为公司贡献收益人民币0.44亿元及人民币0.19亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637"],"gpt_icon":0},{"id":"2570002211","title":"毛利率逼近恒瑞，仿制药年赚1.4亿，海西新药为何二次递表港股？","url":"https://stock-news.laohu8.com/highlight/detail?id=2570002211","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570002211?lang=zh_cn&edition=fundamental","pubTime":"2025-09-26 18:42","pubTimestamp":1758883329,"startTime":"0","endTime":"0","summary":"","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1758834669658440560","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4614","02637","HSTECH","YANG","HSCEI"],"gpt_icon":1},{"id":"2570021883","title":"海西新药递表港股：36名销售撑起4.66亿营收，毛利率超80%逼近恒瑞，靠仿制药年赚1.4亿，关联资金交易引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2570021883","media":"创业最前线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570021883?lang=zh_cn&edition=fundamental","pubTime":"2025-09-26 00:00","pubTimestamp":1758816000,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-09-26/doc-infruesa0734171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02637","HSTECH","YANG","HSCEI"],"gpt_icon":1},{"id":"2567349153","title":"海西新药冲击IPO，用仿制药养创新药，销售费用率较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2567349153","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567349153?lang=zh_cn&edition=fundamental","pubTime":"2025-09-14 16:49","pubTimestamp":1757839777,"startTime":"0","endTime":"0","summary":"在研新药面临激烈的竞争","market":"sg","thumbnail":"https://img2.gelonghui.com/2e7fc-e56d8535-fc24-4298-80ed-697963cc0c72.jpg?guru_height=938&guru_width=1707&guru_size=215191","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/2e7fc-e56d8535-fc24-4298-80ed-697963cc0c72.jpg?guru_height=938&guru_width=1707&guru_size=215191"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2831594","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02637","BK1574","BK1161"],"gpt_icon":0},{"id":"2562782479","title":"二次递表，海西新药国有股权被稀释之迷","url":"https://stock-news.laohu8.com/highlight/detail?id=2562782479","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562782479?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 18:17","pubTimestamp":1756203457,"startTime":"0","endTime":"0","summary":"文｜《投资者网》蔡俊闯关无疾而终后，海西新药再度冲击IPO。期间，监管层关注到股权沿革。国有股权被稀释超50%二次闯关港交所，海西新药的股权沿革被旧事重提。同年，国有股东以2000万元将40%股权转让给康心汕。其实，公司最核心问题在于估值膨胀的过程里国有股权被稀释。递交IPO材料前，福建省国有资本合计持股公司超20%，过程中因转让、换股、融资等稀释了超50%股权。截至目前，公司有14款仿制药获批上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1756173360731640322","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","BK1574","02637"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":45,"code":"91000000","status":"200"}]}}